BioCentury | Sep 15, 2016
Product R&D

Enter GammaDelta

...create its discovery-stage ACTallo cells, an allogeneic γδ T cell therapy platform. Lymphact creates its Delta One T (DOT) cells...
...of the company's ACTallo platform Blood-resident γδ Multiple undisclosed cancers Preclinical Lymphocyte Activation Technologies S.A. Delta One T (DOT) cells...
Items per page:
1 - 1 of 1